IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)

Ischemic Stroke Clinical Trial

— IMPRESS  

Official title:

IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04663399
• Other study ID #: BMR_2020_32
• Status: Recruiting
• Start date: February 23, 2023
• Est. completion date: December 15, 2024

Study information

• Verified date: July 2023
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: Benjamin Maier
• Phone: 0148036556
• Email: bmaier[@]for.paris
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 months of AIC treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: December 15, 2024
• Est. primary completion date: September 15, 2024
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Presenting an acute ischemic stroke for which treatment by mechanical thrombectomy is indicated according to European and North American recommendations (associated or not with intravenous thrombolysis)

Exclusion Criteria:

• Intracranial haemorrhage associated with acute ischemic stroke on initial imaging

• Contraindication or non-indication to a mechanic thrombectomy

• Immunosuppressive treatment or corticosteroid therapy on admission of the patient

• Pre-existing neurological disability limiting the neurological assessment to 3 months (mRS>2 on admission)

• Dementia known and diagnosed pre-existing at acute ischemic stroke

• Pregnant or breastfeeding woman

Related Conditions & MeSH terms

• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke
• Thrombectomy

Intervention

Other:
• Prospective patient
The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.

Locations

Country	Name	City	State
France	Hôpital Fondation Adolphe de Rothschild	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immuno-inflammatory and thrombo-inflammatory profiles in patients suffering from AIC and treated with mechanical Thrombectomie.	Blood plasma collected from patients at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment will be used to discover and validate panels of inflammatory biomarkers that are predictive of therapeutic response. The biomarkers will be measured using a multiplex preconfigured panels for inflammatory biomarkers.	21 months